Design and optimization of carvedilol-loaded transbilosomes for the control of diabetic high-fat diet-induced atherosclerosis in rats
Journal of Pharmacy and Pharmacology · 2026
DOI: 10.1093/jpp/rgaf086 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmacy and Pharmacology, 2026. Verfasst von Marwa M Nagib und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Misr International University, Cairo 11435, Egypt. Hauptthemen laut MEDLINE: Carvedilol, Atherosclerosis, Diabetes Mellitus, Experimental, Adrenergic beta-Antagonists. Die Arbeit nennt 67 Literaturangaben. Gefördert von: Taif University in Saudi Arabia.
Abstract (Originalsprache)
Objectives
Carvedilol (CDL) is an oral beta-adrenergic blocker known for enhancing arterial blood flow and reducing hyperglycemia due to its antioxidant properties. However, CDL’s short half-life leads to its low efficacy and poor bioavailability. This study aimed to develop a nasal spray of CDL-loaded transbilosomes (CTB) to improve CDL’s sustainability, bioavailability, targeting, and effectiveness in controlling atherosclerosis in rats.
Methods
Various CTB formulations were created using a Box–Behnken design to examine the effects of phospholipid, Span 60, and sodium deoxycholate (SDC) levels. In vivo evaluation of this optimal CTB formulation in a rat model of experimental diabetic high-fat diet-induced atherosclerosis was conducted. Key findings The formulation containing 274.33 mg of phospholipid, 26.67 mg of Span 60, and 22.45 mg of SDC was identified as the optimal formulation. When compared with free CDL, the optimal CTB formulation enhanced sustainability, bioavailability, and targeting of CDL by 72.43%, 7.43-fold, and 7.55-fold, respectively. The nasal CTB group showed significant reductions in blood levels of glucose, triglycerides, cholesterol, and LDL, while increasing HDL and survival rates compared with the disease group. A histopathological study confirmed the efficacy of the nasal CTB spray.
Conclusion
The nasal CTB spray could be a potential therapy in controlling atherosclerosis in rats.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Misr International University, Cairo 11435, Egypt.
- Department of Internal Medicine, Hummorabi College of Medicine, University of Babylon, Babil 51002, Iraq.
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Beni-Suef University, Beni-Suef 62511, Egypt.
- Pharmacology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef 62511, Egypt.
- Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, P.O. Box 11099, Taif 21944, Saudi Arabia.
- Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif 11099, Saudi Arabia.
ORCID-Profile: Amr Gamal Fouad
Förderung
- Taif University in Saudi Arabia
Zitieren
APA
Nagib, M. M., Haider, A. H., Fouad, A. G., Khalil, S. F. A., Belal, A., Baali, F. H., Albezrah, N. K. A., Ismail, A., & Abo El-Ela, F. I. (2026). Design and optimization of carvedilol-loaded transbilosomes for the control of diabetic high-fat diet-induced atherosclerosis in rats. Journal of Pharmacy and Pharmacology. https://doi.org/10.1093/jpp/rgaf086
Vancouver
Nagib MM, Haider AH, Fouad AG, Khalil SFA, Belal A, Baali FH, et al. Design and optimization of carvedilol-loaded transbilosomes for the control of diabetic high-fat diet-induced atherosclerosis in rats. Journal of Pharmacy and Pharmacology. 2026. doi:10.1093/jpp/rgaf086
BibTeX
@article{Nagib2026,
author = {Nagib, Marwa M and Haider, Ala Hussain and Fouad, Amr Gamal and Khalil, Sherif Faysal Abdelfattah and Belal, Amany and Baali, Fahad H and Albezrah, Nisreen Khalid Aref and Ismail, Alaa and Abo El-Ela, Fatma I},
title = {Design and optimization of carvedilol-loaded transbilosomes for the control of diabetic high-fat diet-induced atherosclerosis in rats},
journal = {Journal of Pharmacy and Pharmacology},
year = {2026},
doi = {10.1093/jpp/rgaf086}
}
EUVIMED